Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up Interstitial lung disease following severe COVID-19 pneumonia

Main Article Content

Sibel Günay
Izzet Selcuk Parlak
Habibe Hezer
Ebru Şengül Şeref Parlak
Melike Sanem Umut
Zeynep Hancıoğlu
Hülya Çelenk Ergüden
Yasin Kocaman
Aynil Dalkıran
Ümran Sertçelik
İrem Şerifoğlu
Esmehan Akpınar
Muhammet Furkan Göktaş
Meltem Fidan
Büşra Babahanoğlu
Fatma Sinem Cander
Esra Çıvgın https://orcid.org/0000-0003-4790-3146
Mükremin Er
Hatice Kılıç
Emine Argüder
Tuncer Tuğ
Ebru Ünsal
Canan Hasanoğlu
İrem Günay
Muhammet Babayiğit
Büşra Ağca
Ayşegül Karalezli

Keywords

COVID-19, interstitial involvement, steroid treatment, severe pneumonia

Abstract

Background:


We aimed to evaluate the pulmonary involvement status, its related factors, and pulmonary function test (PFT) results in the first month follow-up in patients who were discharged for severe Covid-19 pneumonia, and to assess the efficacy of corticosteroid treatment on these parameters in severe pulmonary involvement patients.


Methods:


We retrospectively analyzed all consecutive patients who applied to our COVID-19 follow-up clinic at the end of the first month of hospital discharge. Functional and radiological differences were compared after 3 months of corticosteroid treatment in severe pulmonary involvement group.


Results


We analyzed 391 patients with “pulmonary parenchymal involvement” (PPIG) and 162 patients with “normal lung radiology” (NLRG). 122 patients in the PPIG (corticosteroid-required interstitial lung disease group (CRILD)) had severe pulmonary involvement with frequent symptoms and required corticosteroid prescription. Pulmonary involvement was more common in males and elder patients (P<0.001, for both). Being smoker and elderly were associated with a higher risk-ratio in predicting to be in PPIG (OR:2.250 and OR:1.057, respectively). Smokers, male and elderly patients, and HFNO2 support during hospitalization were risk factors for being a patient with CRILD (OR:2.737, OR:4.937, OR:4.756, and OR:2.872, respectively). After a three-months of methylprednisolone medication, a good response was achieved on radiological findings and PFT results in CRILD.


Conclusions:


In conclusion, after severe COVID-19 pneumonia, persistent clinical symptoms and pulmonary parenchymal involvement would be inevitable in elder and smoker patients. Moreover, corticosteroid treatment in patients with severe parenchymal involvement was found to be effective in the improvement of radiological and functional parameters.

Downloads

Download data is not yet available.
Abstract 538 | PDF Downloads 352

References

1- https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-february-2023 (last accessed date February 12, 2023)
2- Fahriani M, Ilmawan M, Fajar JK, Maliga HA, Frediansyah A, Masyeni S, et al. 2021; 1(2): e36. doi:10.52225/narraj.v1i2.36
3- Goel N, Goyal N, Nagaraja R, Kumar R. Systemic corticosteroids for management of 'long-COVID': an evaluation after 3 months of treatment. Monaldi Arch Chest Dis. 2021;92(2). doi: 10.4081/monaldi.2021.1981
4- Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Curr Res Pharmacol Drug Discov. 2022; 3: 100086. doi: 10.1016/j.crphar.2022.100086.
5- Fabbri L, Moss S, Khan FA, et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax. 2022 Mar 25:thoraxjnl-2021-218275. doi: 10.1136/thoraxjnl-2021-218275
6- Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020;20:1135–40. doi: 10.1016/S1473-3099(20)30434-5.
7- Ducloyer M, Gaborit B, Toquet C, et al. Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations. Int J Legal Med 2020;134:2209–4. doi:10.1007/s00414-020-02390-1.
8- Zhao L, Wang X, Xiong Y, et al. Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia. Medicine 2021;100:e25232. doi:10.1097/MD.0000000000025232.
9- Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020 Dec;81(6):e4-e6. doi: 10.1016/j.jinf.2020.08.029.
10- Bridi GDP, Tanni SE, Baldi BG. Current Understanding of Post-COVID Pulmonary Fibrosis: Where Are We? Arch Bronconeumol. 2022:S0300-2896(22)00504-X. doi:10.1016/j.arbres.2022.07.014.
11- Polat G, Özdemir Ö, Ermin S, et al. Factors Affecting the Risk of Interstitial Lung Disease Development in Hospitalized Patients With COVID-19 Pneumonia. Respir Care. 2022 ;67(10):1272-1281. doi: 10.4187/respcare.09816.
12- Mylvaganam RJ, Bailey JI, Sznajder JI, Sala MA, Northwestern Comprehensive COVID Center Consortium. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev 2021;30(162):210194
13- Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021 Jul;9(7):747-754. doi: 10.1016/S2213-2600(21)00174-0.
14- COVID-19 Scientific Board and Turkish Ministry of Health General Directorate of Public Health. https://covid19.saglik.gov.tr/TR-66301/covid-19-rehberi.html (Last Accessed: 03 December 2022)
15- British Thoracic Society. British Thoracic Society Guidance on Respiratory Follow Up of Patients with a ClinicoRadiological Diagnosis of COVID-19 Pneumonia [Internet]. 2020. Available from https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/resp-follow-up-guidance-post-covid-pneumonia/
16- Ali RMM, Ghonimy MBI. Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients. Egypt J Radiol Nucl Med. 2021;52(1):101. doi: 10.1186/s43055-021-00484-3.
17- Francone M, Iafrate F, Gorgio M, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020; 4:1–10.
18- Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149–1160
19- Nakayama LF, Urias MG, Gonçalves AS, Ribeiro RA, Macruz TA, Pardo RB. Post-discharge follow-up of patients with COVID-19: A Brazilian experience. SAGE Open Med. 2022 May 12;10:20503121221096602. doi: 10.1177/20503121221096602.
20- Tarraso J, Safont B, Carbonell-Asins JA, et al. Lung function and radiological findings 1 year after COVID-19: a prospective follow-up. Respir Res. 2022 Sep 12;23(1):242. doi: 10.1186/s12931-022-02166-8.
21- Hu T, Liu Y, Zhao M, Zhuang Q, Xu L, He Q. A comparison of COVID-19, SARS and MERS. PeerJ 2020;8:e9725.
22- Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging 2017;27(3): 342-349. doi: 10.4103/ijri.IJRI_469_16
23- Hui DS, Joynt GM, Wong KT, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax 2005;60(5):401-409.
24- Hui DS, Wong KT, Ko FW, et al.. The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest 2005;128(4):2247-2261.
25- Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology 2020;296(2):E55-E64. doi: 10.1148/radiol.2020200843
26- Barash M, Ramalingam V. Post-COVID Interstitial Lung Disease and Other Lung Sequelae. Clin Chest Med. 2023;44(2):263-277.
27- Han X, Fan Y, Alwalid O, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021;299(1):E177-E186.
28- Meiler S, Poschenrieder F, Mohr A, et al. CT findings in “Post-Covid”: residua from acute pneumonia or “Post-Covid-ILD”? . Sarcoidosis Vasc Diffuse Lung Dis 2023;40(2):e2023024.
29- Wells AU, Devaraj A, Desai SR. Interstitial lung disease after COVID-19 infection: a catalog of uncertainties. Radiology 2021;299(1):E216-E218.
30- Gupta VK, Alkandari BM, Mohammed W, Tobar AM, Abdelmohsen MA. Ventilator associated lung injury in severe COVID-19 pneumonia patients - case reports: ventilator associated lung injury in COVID-19. Eur J Radiol Open 2020;8: 100310.
31- COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188): Evidence review 4: investigations. London: National Institute for Health and Care Excellence (NICE); 2020 Dec. (NICE Guideline, No. 188.) Last accessed: 3rd December 2022. Available from: https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742)
32- Funke-Chambour M, Bridevaux PO, Clarenbach CF, et al. Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID. Respiration. 2021;100(8):826-841. doi: 10.1159/000517255.
33- Kumar R, Behera D, Jindal SK, et al. Post-COVID-19 respiratory management: Expert panel report. Respiratory management. Indian J Chest Dis Allied Sci 2020;62:179-91.
34- Bradley B, Branley HM, Egan JJ, et al. British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008 Sep;63 Suppl 5:v1-58. doi: 10.1136/thx.2008.101691.
35- Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann Am Thorac Soc. 2021 May;18(5):799-806. doi: 10.1513/AnnalsATS.202008-1002OC.
36- Dhooria S, Chaudhary S, Sehgal IS, et al. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial). Eur Respir J. 2022 Feb 17;59(2):2102930. doi: 10.1183/13993003.02930-2021.

Most read articles by the same author(s)